Search Results - "Gettinger, Scott"

Phase II Trial of Afatinib in Patients With EGFR -Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.

Authors: Gettinger, Scott N. Song, Zihe Reckamp, Karen L. et al.

Source: JCO Precision Oncology. 12/1/2024, Vol. 8, p1-10. 10p.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors: Herbst, Roy S. Gettinger, Scott N. Horn, Leora et al.

Source: Nature. 11/27/2014, Vol. 515 Issue 7528, p563-567. 5p.

Subjects: Cancer cells, Tumors, T cells, Cytotoxins, Fractalkine

This result is not displayed to guests.
Login for full access.

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Authors: Horn, Leora Gettinger, Scott N. Gordon, Michael S. et al.

Source: European Journal of Cancer. Sep2018, Vol. 101, p201-209. 9p.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

Authors: Horn, Leora Gettinger, Scott Camidge, D. Ross et al.

Source: Lung Cancer (01695002). Nov2017, Vol. 113, p51-58. 8p.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.

Authors: Wakelee, Heather Gettinger, Scott Engelman, Jeffrey et al.

Source: Cancer Chemotherapy & Pharmacology. May2017, Vol. 79 Issue 5, p923-932. 10p.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Authors: Gettinger, Scott N Bazhenova, Lyudmila A Langer, Corey J et al.

Source: Lancet Oncology. Dec2016, Vol. 17 Issue 12, p1683-1696. 14p.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors: Goldberg, Sarah B Gettinger, Scott N Mahajan, Amit et al.

Source: Lancet Oncology. Jul2016, Vol. 17 Issue 7, p976-983. 8p.

SOX2-speciic adaptive immunity and response to immunotherapy in non-small cell lung cancer.

Authors: Dhodapkar, Kavita M. Gettinger, Scott N. Das, Rituparna et al.

Source: OncoImmunology. Jul2013, Vol. 2 Issue 7, pe25205-1-7e25205-1. 7p.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Authors: Goldberg, Sarah B Schalper, Kurt A Gettinger, Scott N et al.

Source: Lancet Oncology. May2020, Vol. 21 Issue 5, p655-663. 9p.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer.

Authors: Liu, Stephen V. Camidge, D. Ross Gettinger, Scott N. et al.

Source: European Journal of Cancer. Sep2018, Vol. 101, p114-122. 9p.

Immuno-thermal ablations - boosting the anticancer immune response.

Authors: Slovak, Ryan Ludwig, Johannes M. Gettinger, Scott N. et al.

Source: Journal for ImmunoTherapy of Cancer. 10/17/2017, Vol. 5, p1-15. 15p.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.

Authors: Abu‐Khalaf, Maysa M. Baumgart, Megan A. Gettinger, Scott N. et al.

Source: Cancer (0008543X). Jun2015, Vol. 121 Issue 11, p1817-1826. 10p.

Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing.

Authors: Narayan, Azeet Carriero, Nicholas J. Gettinger, Scott N. et al.

Source: Cancer Research. Jul2012, Vol. 72 Issue 14, p3492-3498. 7p.

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).

Authors: Lee, Shing M. Fan, Weijia Wang, Aijin et al.

Source: JCO Clinical Cancer Informatics. 4/21/2023, Vol. 7, p1-13. 13p.

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Authors: Cortellini, Alessio Garbo, Edoardo La Cava, Giulia et al.

Source: Lung Cancer (01695002). Nov2025, Vol. 209, pN.PAG-N.PAG. 1p.

NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.

Authors: Rolfo, Christian Drilon, Alexander Hong, David et al.

Source: British Journal of Cancer. Feb2022, Vol. 126 Issue 3, p514-520. 7p.

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas.

Authors: Velcheti, Vamsidhar Schalper, Kurt Yao, Xiaopan et al.

Source: PLoS ONE. Apr2013, Vol. 8 Issue 4, p1-7. 7p.

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Authors: Anagnostou, Valsamo K. Lowery, Frank J. Zolota, Vassiliki et al.

Source: BMC Cancer. 2010, Vol. 10, p186-196. 11p.

Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF.

Authors: Cheok, Stephanie Kim Narayan, Azeet Arnal-Estape, Anna et al.

Source: JCO Precision Oncology. 5/10/2021, Vol. 5, p163-172. 10p.